Biomarin Pharmaceutical (BMRN) Other Working Capital Changes (2009 - 2026)

Biomarin Pharmaceutical has disclosed Other Working Capital Changes across 18 years of filings, most recently posting $11.6 million for Q1 2026.

• Quarterly Other Working Capital Changes rose 82.57% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.7 million (up 49.41% YoY) and the FY2025 annual result came in at -$8.9 million, down 335.34% from the prior year.
• Other Working Capital Changes rose to $11.6 million in Q1 2026, from -$41.0 million in the prior quarter.
• Over five years, Other Working Capital Changes peaked at $36.0 million in Q1 2023 and troughed at -$41.0 million in Q4 2025.
• A 5-year average of $2.9 million and a median of $6.3 million in 2025 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2022 — Other Working Capital Changes plunged 499.78% — and 2023, when it surged 349.39%.
• Tracing BMRN's Other Working Capital Changes over 5 years: stood at -$16.4 million in 2022, then surged by 44.73% to -$9.1 million in 2023, then sank by 78.5% to -$16.2 million in 2024, then sank by 153.8% to -$41.0 million in 2025, then jumped by 128.16% to $11.6 million in 2026.
• Business Quant data shows BMRN's Other Working Capital Changes at $11.6 million in Q1 2026, -$41.0 million in Q4 2025, and $17.0 million in Q3 2025.